Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control.

Trop Med Int Health. 1999 Jan;4(1):5-12. Unique Identifier : AIDSLINE MED/99217817
Verhoeff FH; Brabin BJ; Hart CA; Chimsuku L; Kazembe P; Broadhead RL; Liverpool School of Tropical Medicine, UK.

Abstract: OBJECTIVES: To examine in pregnant women the relationship between HIV infection and malaria prevalence and to determine, in relation to HIV infection, the effectiveness of sulphadoxine-pyrimethamine in clearing P. falciparum infection. METHOD: Descriptive cross-sectional analysis of P. falciparum prevalence in pregnant women at first antenatal visit and of women at delivery who had received two sulphadoxine-pyrimethamine treatments for malaria. HIV status was assessed in 621 women who attended for antenatal care and for delivery at two rural hospitals in southern Malawi in 1993-94. Information was collected on maternal age, parity and gestational age. Prevalence of P. falciparum was measured at first antenatal visit and delivery. Women were given two routine treatment doses of sulphadoxine-pyrimethamine (SP), at first antenatal visit and between 28 and 34 weeks gestation, conforming to Malawi government policy on antimalarial control during pregnancy. RESULTS: Prevalence of HIV infection was 25.6% and all infections were HIV type-1. In primigravidae malaria prevalence at recruitment was 56.3% in HIV-infected and 36.5% in HIV-uninfected women (P=0.04). The corresponding figures for multigravidae were 23.8% and 11.0%, respectively (P<0.01). HIV-infected primigravidae had increased malaria prevalence at all gestational ages. Peak parasite prevalence occurred earlier in gestation in HIV-infected primigravidae (16-19 weeks if HIV-infected; 20-23 weeks if HIV-uninfected). The relative risk for parasitaemia in HIV-infected compared to HIV-uninfected women was significantly increased in three of five parity groups, including the two highest ones (parity>3), indicating parity-specific immunity to malaria was impaired. Malaria prevalence at delivery remained high in HIV-infected women despite prior routine treatment with sulphadoxine-pyrimethamine in pregnancy There was no significant difference in parasite prevalence at delivery between women who did or did not use sulphadoxine-pyrimethamine. CONCLUSIONS: HIV infection is associated with a significant increase in malaria prevalence in pregnant women of all parities with the effect apparent from early in gestation. Two treatment doses of sulphadoxine-pyrimethamine were inadequate to clear parasitaemia in many women by the time of delivery and this occurred independently of HIV status and despite high sensitivity to SP in this area. There is a need to undertake longitudinal studies to determine the incidence of P. falciparum infection in HIV-infected and uninfected pregnant women and to reassess the frequency and timing of sulphadoxine-pyrimethamine treatment doses in these women. Late pregnancy re-infections with P. falciparum probably explain the high parasite prevalence at delivery following sulphadoxine-pyrimethamine treatment at 28-34 weeks gestation.
Keywords: JOURNAL ARTICLE Adult Antimalarials/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*DRUG THERAPY/PARASITOLOGY Cross-Sectional Studies Drug Combinations Drug Resistance Female Gestational Age Human Malaria, Falciparum/*DRUG THERAPY/PARASITOLOGY Malawi Parity Pregnancy Pregnancy Complications, Infectious/*DRUG THERAPY/PARASITOLOGY Prevalence Pyrimethamine/*THERAPEUTIC USE Risk Factors Sulfadoxine/*THERAPEUTIC USE Support, Non-U.S. Gov'tKWDjournalarticleadultantimalarials/KWDtherapeuticuseaids-relatedopportunisticinfections/KWDdrugtherapy/parasitologycross-sectionalstudiesdrugcombinationsdrugresistancefemalegestationalagehumanmalaria,falciparum/KWDdrugtherapy/parasitologymalawiparitypregnancypregnancycomplications,infectious/KWDdrugtherapy/parasitologyprevalencepyrimethamine/KWDtherapeuticuseriskfactorssulfadoxine/KWDtherapeuticusesupport,non-uKWDsKWDgov't
990730
A9971182

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .